Benefits of pre-surgical immunotherapy were independent of race in patients with aggressive breast cancer
Treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy, according to phase I/II clinical trial results published ...
Jul 29, 2022
0
2